Blisovi Fe 1.5/30 Kit
Product Images NDC 68180-869

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Blisovi Fe 1.5/30 (NDC 68180-869). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Lupin Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image-1 (627be501 2e20 4aa0 8fc9 86e3c67250c4 01)

This text provides information about Norethindrone Acetate, giving its chemical name and molecular weight (340.46 g/mol). It is likely a pharmaceutical compound or substance.*

FDA Label Image

Image-2 (627be501 2e20 4aa0 8fc9 86e3c67250c4 02)

This is a description of Ethinyl Estradiol, a compound with the molecular formula C20H24O and a molecular weight of 296.40. Ethinyl Estradiol is commonly used in hormonal contraceptives and hormone replacement therapy.*

FDA Label Image

Image-3 (627be501 2e20 4aa0 8fc9 86e3c67250c4 03)

This text provides a table showing circulatory disease mortality rates per 100,000 woman-years categorized by age, smoking status, and oral contraceptive use. The table displays mortality rates for different subgroups and highlights the impact of smoking status and oral contraceptive use on circulatory disease mortality among women of different age groups. The data presented can be used for research or analysis on the relationship between these factors and circulatory disease mortality rates.*

FDA Label Image

Image-4 (627be501 2e20 4aa0 8fc9 86e3c67250c4 04)

This text provides a comparative analysis from various studies on the use of combined oral contraceptives (COC). It includes data on the risk ratios (RR), odds ratios (OR), and hazard ratios (HR) of using COC versus never using COC. The studies mentioned are from different cohorts and offer insight into the potential effects of COC use on women's health.*

FDA Label Image

Image-5 (627be501 2e20 4aa0 8fc9 86e3c67250c4 05)

This text indicates that "LUPIN" and "**the" are registered trademarks of Lupin Pharmaceuticals, Inc.*

FDA Label Image

Image-6 (627be501 2e20 4aa0 8fc9 86e3c67250c4 06)

This resource provides instructions for starting birth control pills for both Sunday starters and day 1 starters. If your period does not start on a Sunday, you should follow the day label strip starting from the first day of your period. The days of the week and pill sequence are provided for easy reference. Remember to take the pills in the direction from left to right each week.*

FDA Label Image

Image-7 (627be501 2e20 4aa0 8fc9 86e3c67250c4 07)

This text provides instructions for starting birth control pills on the first day of your period. It indicates that if your period starts on a day other than Sunday, you should use the day label strip that corresponds to the first day of your period. The text also includes a visual representation of a weekly pill pack with days labeled from Sunday to Saturday and arrows indicating the direction to take the pills each week from left to right.*

FDA Label Image

Image-8 (627be501 2e20 4aa0 8fc9 86e3c67250c4 08)

This is a statement indicating that "LUPIN" and "**the" are registered trademarks owned by Lupin Pharmaceuticals, Inc.*

FDA Label Image

Image-9 (627be501 2e20 4aa0 8fc9 86e3c67250c4 09)

FDA Label Image

Image-10 (627be501 2e20 4aa0 8fc9 86e3c67250c4 10)

This is a description of a medication with two different strengths listed: 1.5 mg and 0.03 mg. The ratio of the two components is 50:1.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.